Inhibition of NETs by systemic administration of DNase I or the use of a PAD4−/− model, largely improves the efficacy of﻿ anti-PD-1 immunotherapy, which is manifested by reduced tumor growth, increased tumor-associated CD8+ T cell infiltration and cytotoxicity. This evidence concerns the gene CD8A and neoplasm.